AMENDMENTS TO THE CLAIMS

This listing of claims will replace all prior versions and listings of claims in the application:

LISTING OF CLAIMS:

1.-81. (cancelled).

82. (previously presented) A substantially pure CsaE polypeptide of SEQ ID NO:10.

83. (currently amended) A substantially pure polypeptide:

(a) having at least 95% amino acid sequence homology over the entire length of ~~with~~ the polypeptide of SEQ ID NO:10, and

(b) that induces a protective immune response to enterotoxigenic *Escherichia coli*.

84. (previously presented) A substantially pure CsaE polypeptide resulting from recombinant expression of the polynucleotide of SEQ ID NO:9.

85. (currently amended) A substantially pure CsaE polypeptide:

(a) which is a product of ~~resulting from~~ recombinant expression of a polynucleotide, wherein the coding strand of said polynucleotide ~~that~~ hybridizes under high stringency with the full-length, non-coding strand of the polynucleotide of SEQ ID NO:9, and

(b) that induces a protective immune response to enterotoxigenic *Escherichia coli*.

86. (previously presented) An immunogenic composition consisting essentially of ~~comprising~~ a substantially pure CsaE polypeptide of any one of claims 82-85 and a pharmaceutically acceptable carrier or diluent.

87. (previously presented) The immunogenic composition of claim 86, wherein the pharmaceutically-acceptable carrier or diluent comprises one or more components suitable for parenteral administration.

88. (previously presented) The immunogenic composition of claim 86, wherein the pharmaceutically-acceptable carrier or diluent comprises one or more components suitable for intranasal administration.

89. (previously presented) The immunogenic composition of claim 86, wherein the pharmaceutically-acceptable carrier or diluent comprises one or more components suitable for intramuscular administration.

90. (previously presented) The immunogenic composition of claim 86, wherein the pharmaceutically-acceptable carrier or diluent comprises one or more components suitable for enteric administration.

91. (previously presented) The immunogenic composition of claim 86, wherein the pharmaceutically-acceptable carrier or diluent is an adjuvant.

92.-93. (cancelled).

94. (new) An immunogenic composition consisting essentially of:

(a) a substantially pure polypeptide selected from the group consisting of:

(i) a polypeptide of SEQ ID NO:10,

(ii) a polypeptide having at least 95% amino acid sequence homology over the entire length of the polypeptide of SEQ ID NO:10 and that induces a protective immune response to enterotoxigenic *Escherichia coli*,

(iii) a polypeptide resulting from recombinant expression of the polynucleotide of SEQ ID NO:9, and

(iv) a polypeptide which is a product of recombinant expression of a polynucleotide, wherein the coding strand of said polynucleotide hybridizes under high stringency with the full-length, non-coding strand of the polynucleotide of SEQ ID NO:9, and that induces a protective immune response to enterotoxigenic *Escherichia coli*,

(b) substantially pure CS4 antigen or substantially pure CsaB polypeptide, or both, and

(c) a pharmaceutically acceptable carrier or diluent.